Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
MAGENTA trial: what clinicians have said so far
Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen
- NCT03081910 ↗
- Active, not recruiting
- Baylor College of Medicine
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on MAGENTA (T-cell malignancies expressing CD5 antigen) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on MAGENTA so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- Phase 1 Therapy With Manufactured Autologous T-Cells Expressing a Second Generation Chimeric Antigen Receptor (CAR) for Treatment of T-Cell Malignancies Expressing CD5 Antigen
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- T-cell Acute Lymphoblastic Lymphoma; T-non-Hodgkin Lymphoma; T-cell Acute Lymphoblastic Leukemia
- Interventions
- Autologous CD5.CAR/28zeta CAR T cells; Allogeneic CD5.CAR/28zeta CAR T cells
- Arms
- Autologous CD5.CAR/28zeta CAR T cells (Group A) - NOW CLOSED · Experimental
- Allogeneic CD5.CAR/28zeta CAR T cells (Group B) · Experimental
- Enrollment
- 104
- Primary outcomes
- Dose limiting toxicity (DLT) rate
- Sponsor
- Baylor College of Medicine with Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital Research Institute, National Cancer Institute (NCI)
- Start
- Nov 1, 2017
- Primary completion
- Jun 1, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT03081910 · updated Nov 4, 2026
Publications
linked from the registry- Dai Z, Mu W, Zhao Y, Jia X, Liu J, Wei Q, Tan T, Zhou J. The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains. Mol Ther. 2021 Sep 1;29(9):2707-2722. doi: 10.1016/j.ymthe.2021.07.001. Epub 2021 Jul 16. PubMed 34274536